Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis

S. Gerdes

Psoriasis Center at the Department of Dermatology, University Clinic of Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany

Search for more papers by this author

V.A. Zahl,

V.A. Zahl

Psoriasis Center at the Department of Dermatology, University Clinic of Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany

Search for more papers by this author

H. Knopf,

H. Knopf

RKI 22, Epidemiology of Non-Communicable Diseases, Robert Koch-Institut, Berlin, Germany

Search for more papers by this author

M. Weichenthal,

M. Weichenthal

Psoriasis Center at the Department of Dermatology, University Clinic of Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany

Search for more papers by this author

U. Mrowietz,

U. Mrowietz

Psoriasis Center at the Department of Dermatology, University Clinic of Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany

Search for more papers by this author

S. Gerdes,

S. Gerdes

Psoriasis Center at the Department of Dermatology, University Clinic of Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany

Search for more papers by this author

V.A. Zahl,

V.A. Zahl

Psoriasis Center at the Department of Dermatology, University Clinic of Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany

Search for more papers by this author

H. Knopf,

H. Knopf

RKI 22, Epidemiology of Non-Communicable Diseases, Robert Koch-Institut, Berlin, Germany

Search for more papers by this author

M. Weichenthal,

M. Weichenthal

Psoriasis Center at the Department of Dermatology, University Clinic of Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany

Search for more papers by this author

U. Mrowietz,

U. Mrowietz

Psoriasis Center at the Department of Dermatology, University Clinic of Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany

Search for more papers by this author

First published: 20 October 2008

https://doi.org/10.1111/j.1365-2133.2008.08786.x

Citations: 23

Sascha Gerdes.
E-mail:[email protected]

Conflicts of interest
None declared.

Share a link

Email
Wechat
Bluesky

Summary

Background Psoriasis is a common dermatological disorder characterized by an immune-mediated chronic inflammation which is associated with a variety of other diseases commonly referred to as comorbidities. The treatments for these diseases may interfere with the course and the treatment of psoriasis. Little is known on the general drug intake of patients with psoriasis.

Objectives To gain more insight into the general drug intake of patients with severe psoriasis. A correlation of comedication to respective diseases could lead to a better knowledge of comorbidities.

Methods Data on demographics, comedication and comorbidities from 1203 patients with severe psoriasis in Germany were analysed. As a control group data from 7099 subjects from the German National Health Survey 1998 were used.

Results Patients with severe psoriasis are receiving significantly more different systemic drugs on average than the general population, with the most prominent difference in multidrug treatment. Drugs used in the treatment of arterial hypertension, diabetes mellitus and other diseases of the metabolic syndrome as well as oral anticoagulants and anticonvulsant agents showed the greatest differences. Special characteristics of antihypertensive drug treatments could be determined.

Conclusions The data obtained in this study provide the basis for an improved management of patients with psoriasis. Knowledge of existing comedication and comorbidities may lead to the ability to treat psoriasis and comorbidities at the same time more safely and to use possible synergistic effects.

References

1 Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263–71.
10.1016/S0140-6736(07)61128-3
CAS PubMed Web of Science® Google Scholar
2 Elder JT. PSORS1: linking genetics and immunology. J Invest Dermatol 2006; 126: 1205–6.
10.1038/sj.jid.5700357
CAS PubMed Web of Science® Google Scholar
3 Mrowietz U, Elder JT, Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 2006; 298: 309–19.
10.1007/s00403-006-0707-8
PubMed Web of Science® Google Scholar
4 Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003; 4: 441–7.
10.2165/00128071-200304070-00001
PubMed Web of Science® Google Scholar
5 Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982–6.
10.1016/0190-9622(95)91336-X
CAS PubMed Web of Science® Google Scholar
6 Pearce DJ, Morrison AE, Higgins KB et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat 2005; 16: 319–23.
10.1080/09546630500335977
PubMed Web of Science® Google Scholar
7 Cohen AD, Bonneh DY, Reuveni H et al. Drug exposure and psoriasis vulgaris: case–control and case–crossover studies. Acta Derm Venereol (Stockh) 2005; 85: 299–303.
10.1080/00015550510032823
CAS PubMed Web of Science® Google Scholar
8 Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol 2000; 1: 159–65.
10.2165/00128071-200001030-00003
CAS PubMed Google Scholar
9 Bellach BM, Knopf H, Thefeld W. [The German Health Survey. 1997/98]. Gesundheitswesen 1998; 60 (Suppl. 2): S59–68.
PubMed Google Scholar
10 Robert Koch-Institut. Public Use File BGS98, Bundes-Gesundheitssurvey 1998. Berlin: Robert Koch-Institut, 2000.
Google Scholar
11 Knopf H, Melchert HU. Bundes-Gesundheitssurvey: Arzneimittelgebrauch. Konsumverhalten in Deutschland. Beiträge zur Gesundheitsberichterstattung des Bundes. Berlin: Robert Koch-Institut, 2003; 1–132.
Google Scholar
12 Gilleaudeau P, Vallat VP, Carter DM et al. Angiotensin-converting enzyme inhibitors as possible exacerbating drugs in psoriasis. J Am Acad Dermatol 1993; 28: 490–2.
10.1016/S0190-9622(08)81761-6
PubMed Web of Science® Google Scholar
13 Sommer DM, Jenisch S, Suchan M et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321–8.
10.1007/s00403-006-0703-z
PubMed Web of Science® Google Scholar
14 Akay A, Pekcanlar A, Bozdag KE et al. Assessment of depression in subjects with psoriasis vulgaris and lichen planus. J Eur Acad Dermatol Venereol 2002; 16: 347–52.
10.1046/j.1468-3083.2002.00467.x
CAS PubMed Web of Science® Google Scholar
15 Esposito M, Saraceno R, Giunta A et al. An Italian study on psoriasis and depression. Dermatology 2006; 212: 123–7.
10.1159/000090652
PubMed Web of Science® Google Scholar
16 Yang Y, Koh D, Khoo L et al. The psoriasis disability index in Chinese patients: contribution of clinical and psychological variables. Int J Dermatol 2005; 44: 925–9.
10.1111/j.1365-4632.2004.02237.x
CAS PubMed Web of Science® Google Scholar
17 O’Brien M, Koo J. The mechanism of lithium and beta-blocking agents in inducing and exacerbating psoriasis. J Drugs Dermatol 2006; 5: 426–32.
PubMed Google Scholar
18 Lindegård B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986; 172: 298–304.
10.1159/000249365
CAS PubMed Web of Science® Google Scholar
19 Kwan SY, Lin JH, Su MS. Coexistence of epilepsy, myasthenia gravis and psoriasis vulgaris. Zhonghua Yi Xue Za Zhi (Taipei) 2000; 63: 153–7.
CAS PubMed Google Scholar
20 Abel EA, DiCicco LM, Orenberg EK et al. Drugs in exacerbation of psoriasis. J Am Acad Dermatol 1986; 15: 1007–22.
10.1016/S0190-9622(86)70265-X
CAS PubMed Web of Science® Google Scholar
21 Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007; 143: 1559–65.
10.1001/archderm.143.12.1559
PubMed Web of Science® Google Scholar
22 Van De Kerkhof PC, Kragballe K, Austad J et al. Psoriasis: severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severity. Eur J Dermatol 2006; 16: 167–71.
PubMed Web of Science® Google Scholar
23 Mallbris L, Akre O, Granath F et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225–30.
10.1023/B:EJEP.0000020447.59150.f9
PubMed Web of Science® Google Scholar
24 Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735–41.
10.1001/jama.296.14.1735
CAS PubMed Web of Science® Google Scholar
25 Ludwig RJ, Herzog C, Rostock A et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007; 156: 271–6.
10.1111/j.1365-2133.2006.07562.x
CAS PubMed Web of Science® Google Scholar
26 Wakkee M, Thio HB, Prens EP et al. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007; 190: 1–9.
10.1016/j.atherosclerosis.2006.07.011
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume159, Issue5

November 2008

Pages 1116-1123

Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis

Summary

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis

Summary

References

Citing Literature

References

Related

Information